Hepatitis B Virus News and Research

RSS

Optimal use of combination therapy achieves best treatment outcomes in patients with CHB

Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB).

16 Apr 2014

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

Data from a late-breaking abstract presented at the International Liver CongressTM 2014 identifies a new compound, SBEL1, that has the ability to inhibit hepatitis C virus (HCV) activity in cells at several points in the virus' lifecycle.

15 Apr 2014

New drug combination proves effective in treating patients with HCV genotype 1

Treatment options for the 170 million people worldwide with chronic Hepatitis C Virus (HCV) are evolving rapidly, although the available regimens often come with significant side effects. Two multi-center clinical trials led by Beth Israel Deaconess Medical Center show promise for a new option that could help lead to both an increase in patients cured with a much more simple and tolerable all oral therapy.

15 Apr 2014

High cost of potent hepatitis drug presents challenges across the U.S.

Sovaldi, the hepatitis C treatment drug, is considered a breakthrough for patients with the disease. However, since, it won federal approval in December, lawmakers, insurers and patient advocates have begun an all-out revolt over it's high price point of $1,000 a daily pill or $84,000 over 12 weeks of treatment.

15 Apr 2014

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

Twelve weeks of an investigational oral therapy cured hepatitis C infection in more than 90 percent of patients with liver cirrhosis and was well tolerated by these patients, according to an international study that included researchers from UT Medicine San Antonio and the Texas Liver Institute.

15 Apr 2014

Viral hepatitis linked to more deaths than HIV across EU countries

Mortality from viral hepatitis is significantly higher than from HIV/AIDS across EU countries, according to results from The Global Burden of Disease Study 2010 (GBD 2010) which was announced for the first time today at the International Liver CongressTM 2014.

11 Apr 2014

Assembly Pharmaceuticals, BioCrossroads develop novel drugs that have potential to treat chronic HBV infection

Assembly Pharmaceuticals and BioCrossroads today announced that the BioCrossroads Indiana Seed Fund II has made an investment in Assembly Pharmaceuticals. Assembly is developing novel drugs for the treatment and potential cure of chronic hepatitis B virus (HBV) infection.

10 Apr 2014

Johns Hopkins student receives 2014 Excellence in Public Health Award

Ramy El-Diwany, a fifth-year M.D./Ph.D. student at the Johns Hopkins University School of Medicine, has won a 2014 Excellence in Public Health Award from the U.S. Public Health Service (USPHS) Physician Professional Advisory Committee for his contributions to community health services.

10 Apr 2014

Gilead Sciences announces positive results from LDV/SOF phase 2 studies on HCV infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF) for the treatment of chronic hepatitis C virus (HCV) infection.

10 Apr 2014

Small financial incentives can improve people’s completion of HBV vaccination, study finds

Small financial incentives, totalling as little as £30, can dramatically increase the likelihood of people who inject drugs completing a course of hepatitis B virus (HBV) vaccination, according to new research published in The Lancet.

10 Apr 2014

Janssen begins Phase 3 OPTIMIST trials for treatment of chronic Genotype 1 HCV infection

Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis.

3 Apr 2014

Gilead reports topline results from sofosbuvir Phase 3 trial in Japan for treatment of HCV infection

Gilead Sciences, Inc. today announced topline results from a Phase 3 clinical trial (Study GS-US-334-0118) in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin (RBV) for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection.

3 Apr 2014

ABL enters into licensing agreement with CRP-Santé for COMET software

Advanced Biological Laboratories (ABL) S.A., a Luxembourg-based company today announced that it has entered into an exclusive worldwide licensing agreement with CRP-Santé, a Luxembourg-based public research center active in the field of clinically oriented biomedical research, for its COMET (COntext-based Modeling for Expeditious Typing) software, a tool designed to rapidly analyze and optimally subtype large genetic data sets arising from epidemiological or antiretroviral resistance in the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) fields.

2 Apr 2014

NeuroVive presents clinical data of NVP018 for treatment of chronic hepatitis B infections at EASL

NeuroVive's anti-viral preclinical program, with compound designated NVP018, has generated significant data indicating that NVP018 has the potential to become an effective alternative or addition to current drugs for treating chronic hepatitis B infections.

29 Mar 2014

SLU researchers awarded NIH grants to search for a drug to cure hepatitis B

Two grants from the National Institutes of Health will allow Saint Louis University researchers to build on breakthroughs in understanding the hepatitis B virus and begin the search for a drug to cure - not just halt - the illness.

26 Mar 2014

Medivir announces phase III ATTAIN study of simeprevir inhibitor in treatment of adult patients with HCV

Medivir AB today announced that new phase III data for the once-daily protease inhibitor simeprevir have been presented at the Conference of the Asian Pacific Association for the Study of the Liver (APASL) in Brisbane, Australia.

19 Mar 2014

Patients with both HIV and hepatitis C have 80% higher rates of serious liver disease

A new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania has found that the risk of hepatitis C-associated serious liver disease persists in HIV patients otherwise benefitting from antiretroviral therapy (ART) to treat HIV.

18 Mar 2014

Hepatitis B Virus News and Research

Optimal use of combination therapy achieves best treatment outcomes in patients with CHB

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

New drug combination proves effective in treating patients with HCV genotype 1

High cost of potent hepatitis drug presents challenges across the U.S.

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

Viral hepatitis linked to more deaths than HIV across EU countries

Assembly Pharmaceuticals, BioCrossroads develop novel drugs that have potential to treat chronic HBV infection

Johns Hopkins student receives 2014 Excellence in Public Health Award

Gilead Sciences announces positive results from LDV/SOF phase 2 studies on HCV infection

Small financial incentives can improve people’s completion of HBV vaccination, study finds

Janssen begins Phase 3 OPTIMIST trials for treatment of chronic Genotype 1 HCV infection

Gilead reports topline results from sofosbuvir Phase 3 trial in Japan for treatment of HCV infection

ABL enters into licensing agreement with CRP-Santé for COMET software

NeuroVive presents clinical data of NVP018 for treatment of chronic hepatitis B infections at EASL

SLU researchers awarded NIH grants to search for a drug to cure hepatitis B

Medivir announces phase III ATTAIN study of simeprevir inhibitor in treatment of adult patients with HCV

Patients with both HIV and hepatitis C have 80% higher rates of serious liver disease

Hepatitis C patients with ITPA gene variants exhibit lower risk of relapse after treatment

Parasites in human are most likely to interact via food source

Experimental drugs offer hope for people with hepatitis C

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News